Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-039063
Filing Date
2023-05-12
Accepted
2023-05-12 16:31:08
Documents
64
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0323_pasitheatherap.htm   iXBRL 10-Q 521316
2 CERTIFICATION f10q0323ex31-1_pasitheathe.htm EX-31.1 11353
3 CERTIFICATION f10q0323ex31-2_pasitheathe.htm EX-31.2 11556
4 CERTIFICATION f10q0323ex32-1_pasitheathe.htm EX-32.1 5044
5 CERTIFICATION f10q0323ex32-2_pasitheathe.htm EX-32.2 4555
  Complete submission text file 0001213900-23-039063.txt   4169164

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ktta-20230331.xsd EX-101.SCH 53212
7 XBRL CALCULATION FILE ktta-20230331_cal.xml EX-101.CAL 28801
8 XBRL DEFINITION FILE ktta-20230331_def.xml EX-101.DEF 210321
9 XBRL LABEL FILE ktta-20230331_lab.xml EX-101.LAB 433730
10 XBRL PRESENTATION FILE ktta-20230331_pre.xml EX-101.PRE 230230
58 EXTRACTED XBRL INSTANCE DOCUMENT f10q0323_pasitheatherap_htm.xml XML 514395
Mailing Address 2110 NARCISSUS CT VENICE CA 90291
Business Address 2110 NARCISSUS CT VENICE CA 90291 8184226172
Pasithea Therapeutics Corp. (Filer) CIK: 0001841330 (see all company filings)

EIN.: 851591963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40804 | Film No.: 23916343
SIC: 2834 Pharmaceutical Preparations